TISIDB

Summary
Symbol	ERO1A
Name	endoplasmic reticulum oxidoreductase alpha
Aliases	ERO1-alpha; Ero1alpha; ERO1L; ERO1 (S. cerevisiae)-like; ERO1-like (S. cerevisiae); ERO1-L; ERO1-L-alpha; ER ......
Chromosomal Location	14q22.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Endoplasmic reticulum membrane Peripheral membrane protein Lumenal side Note=The association with ERP44 is essential for its retention in the endoplasmic reticulum.
Domain	PF04137 Endoplasmic Reticulum Oxidoreductin 1 (ERO1)
Function	Oxidoreductase involved in disulfide bond formation in the endoplasmic reticulum. Efficiently reoxidizes P4HB/PDI, the enzyme catalyzing protein disulfide formation, in order to allow P4HB to sustain additional rounds of disulfide formation. Following P4HB reoxidation, passes its electrons to molecular oxygen via FAD, leading to the production of reactive oxygen species (ROS) in the cell. Required for the proper folding of immunoglobulins. Involved in the release of the unfolded cholera toxin from reduced P4HB/PDI in case of infection by V.cholerae, thereby playing a role in retrotranslocation of the toxin. Plays an important role in ER stress-induced, CHOP-dependent apoptosis by activating the inositol 1,4,5-trisphosphate receptor IP3R1.

> Gene Ontology [ TOP ]
Biological Process	GO:0000302 response to reactive oxygen species GO:0001666 response to hypoxia GO:0006457 protein folding GO:0006458 'de novo' protein folding GO:0006575 cellular modified amino acid metabolic process GO:0006816 calcium ion transport GO:0006874 cellular calcium ion homeostasis GO:0006875 cellular metal ion homeostasis GO:0006979 response to oxidative stress GO:0006986 response to unfolded protein GO:0007204 positive regulation of cytosolic calcium ion concentration GO:0007568 aging GO:0009266 response to temperature stimulus GO:0010260 animal organ senescence GO:0019471 4-hydroxyproline metabolic process GO:0022417 protein maturation by protein folding GO:0030198 extracellular matrix organization GO:0030968 endoplasmic reticulum unfolded protein response GO:0032844 regulation of homeostatic process GO:0032845 negative regulation of homeostatic process GO:0034620 cellular response to unfolded protein GO:0034975 protein folding in endoplasmic reticulum GO:0034976 response to endoplasmic reticulum stress GO:0035966 response to topologically incorrect protein GO:0035967 cellular response to topologically incorrect protein GO:0036293 response to decreased oxygen levels GO:0036294 cellular response to decreased oxygen levels GO:0043062 extracellular structure organization GO:0045444 fat cell differentiation GO:0045454 cell redox homeostasis GO:0050873 brown fat cell differentiation GO:0051084 'de novo' posttranslational protein folding GO:0051085 chaperone mediated protein folding requiring cofactor GO:0051208 sequestering of calcium ion GO:0051209 release of sequestered calcium ion into cytosol GO:0051235 maintenance of location GO:0051238 sequestering of metal ion GO:0051282 regulation of sequestering of calcium ion GO:0051283 negative regulation of sequestering of calcium ion GO:0051480 regulation of cytosolic calcium ion concentration GO:0051604 protein maturation GO:0055074 calcium ion homeostasis GO:0060401 cytosolic calcium ion transport GO:0060402 calcium ion transport into cytosol GO:0061077 chaperone-mediated protein folding GO:0070059 intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress GO:0070482 response to oxygen levels GO:0070509 calcium ion import GO:0070588 calcium ion transmembrane transport GO:0070838 divalent metal ion transport GO:0071453 cellular response to oxygen levels GO:0071456 cellular response to hypoxia GO:0072503 cellular divalent inorganic cation homeostasis GO:0072507 divalent inorganic cation homeostasis GO:0072511 divalent inorganic cation transport GO:0097193 intrinsic apoptotic signaling pathway GO:0097553 calcium ion transmembrane import into cytosol GO:1901605 alpha-amino acid metabolic process GO:1902656 calcium ion import into cytosol GO:2000021 regulation of ion homeostasis
Molecular Function	GO:0003756 protein disulfide isomerase activity GO:0015035 protein disulfide oxidoreductase activity GO:0015036 disulfide oxidoreductase activity GO:0016667 oxidoreductase activity, acting on a sulfur group of donors GO:0016671 oxidoreductase activity, acting on a sulfur group of donors, disulfide as acceptor GO:0016853 isomerase activity GO:0016860 intramolecular oxidoreductase activity GO:0016864 intramolecular oxidoreductase activity, transposing S-S bonds
Cellular Component	GO:0005788 endoplasmic reticulum lumen GO:0030425 dendrite

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa04141 Protein processing in endoplasmic reticulum
Reactome	R-HSA-2262752: Cellular responses to stress R-HSA-3299685: Detoxification of Reactive Oxygen Species R-HSA-264876: Insulin processing R-HSA-392499: Metabolism of proteins R-HSA-2980736: Peptide hormone metabolism

Summary
Symbol	ERO1A
Name	endoplasmic reticulum oxidoreductase alpha
Aliases	ERO1-alpha; Ero1alpha; ERO1L; ERO1 (S. cerevisiae)-like; ERO1-like (S. cerevisiae); ERO1-L; ERO1-L-alpha; ER ......
Chromosomal Location	14q22.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between ERO1A and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	ERO1A
Name	endoplasmic reticulum oxidoreductase alpha
Aliases	ERO1-alpha; Ero1alpha; ERO1L; ERO1 (S. cerevisiae)-like; ERO1-like (S. cerevisiae); ERO1-L; ERO1-L-alpha; ER ......
Chromosomal Location	14q22.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of ERO1A in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	logFC: -2.44; FDR: 0.04630	Resistant to T cell-mediated killing
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	ERO1A
Name	endoplasmic reticulum oxidoreductase alpha
Aliases	ERO1-alpha; Ero1alpha; ERO1L; ERO1 (S. cerevisiae)-like; ERO1-like (S. cerevisiae); ERO1-L; ERO1-L-alpha; ER ......
Chromosomal Location	14q22.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of ERO1A in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	0	1
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	0	1
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	0	1
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	1
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	1
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	1
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0	1
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	0	1
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0	1
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	-0.109	0.945
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	0.735	0.745
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	-0.026	0.832

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of ERO1A in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	7.1	0	7.1	0.452
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	10	0	10	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	3.7	1.4	2.3	0.469
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	3.7	1.7	2	0.532
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	4.8	0	4.8	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	7.7	0	7.7	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	11.1	0	11.1	0.36
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	20	0	20	0.357
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	2.6	0	2.6	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	0	0	0	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	6.2	0	6.2	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	ERO1A
Name	endoplasmic reticulum oxidoreductase alpha
Aliases	ERO1-alpha; Ero1alpha; ERO1L; ERO1 (S. cerevisiae)-like; ERO1-like (S. cerevisiae); ERO1-L; ERO1-L-alpha; ER ......
Chromosomal Location	14q22.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of ERO1A. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	ERO1A
Name	endoplasmic reticulum oxidoreductase alpha
Aliases	ERO1-alpha; Ero1alpha; ERO1L; ERO1 (S. cerevisiae)-like; ERO1-like (S. cerevisiae); ERO1-L; ERO1-L-alpha; ER ......
Chromosomal Location	14q22.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of ERO1A. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by ERO1A. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	ERO1A
Name	endoplasmic reticulum oxidoreductase alpha
Aliases	ERO1-alpha; Ero1alpha; ERO1L; ERO1 (S. cerevisiae)-like; ERO1-like (S. cerevisiae); ERO1-L; ERO1-L-alpha; ER ......
Chromosomal Location	14q22.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of ERO1A. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	ERO1A
Name	endoplasmic reticulum oxidoreductase alpha
Aliases	ERO1-alpha; Ero1alpha; ERO1L; ERO1 (S. cerevisiae)-like; ERO1-like (S. cerevisiae); ERO1-L; ERO1-L-alpha; ER ......
Chromosomal Location	14q22.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of ERO1A expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	ERO1A
Name	endoplasmic reticulum oxidoreductase alpha
Aliases	ERO1-alpha; Ero1alpha; ERO1L; ERO1 (S. cerevisiae)-like; ERO1-like (S. cerevisiae); ERO1-L; ERO1-L-alpha; ER ......
Chromosomal Location	14q22.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between ERO1A and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	ERO1A
Name	endoplasmic reticulum oxidoreductase alpha
Aliases	ERO1-alpha; Ero1alpha; ERO1L; ERO1 (S. cerevisiae)-like; ERO1-like (S. cerevisiae); ERO1-L; ERO1-L-alpha; ER ......
Chromosomal Location	14q22.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting ERO1A collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse ERO1A